|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM163578982 |
| 003 |
DE-627 |
| 005 |
20231223100643.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0545.xml
|
| 035 |
|
|
|a (DE-627)NLM163578982
|
| 035 |
|
|
|a (NLM)16781892
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yang, Li-Tao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.09.2006
|
| 500 |
|
|
|a Date Revised 09.12.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The role of cell-mediated immunity in human SARS-CoV infection is still not well understood. In this study, we found that memory T-cell responses against the spike (S) protein were persistent for more than 1 year after SARS-CoV infection by detecting the production of IFN-gamma using ELISA and ELISpot assays. Flow cytometric analysis showed that both CD4(+) and CD8(+) T cells were involved in cellular responses against SARS-CoV infection. Interestingly, most of SARS-CoV S-specific memory CD4(+) T cells were central memory cells expressing CD45RO(+) CCR7(+) CD62L(-). However, the majority of memory CD8(+) T cells revealed effector memory phenotype expressing CD45RO(-) CCR7(-) CD62L(-). Thus, our study provides the evidence that SARS-CoV infection in humans can induce cellular immune response that is persistent for a long period of time. These data may have an important implication in the possibility of designing effective vaccine against SARS-CoV infection, specifically in defining T-cell populations that are implicated in protective immunity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, Viral
|2 NLM
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Spike Glycoprotein, Coronavirus
|2 NLM
|
| 650 |
|
7 |
|a Viral Envelope Proteins
|2 NLM
|
| 650 |
|
7 |
|a spike glycoprotein, SARS-CoV
|2 NLM
|
| 650 |
|
7 |
|a spike protein, mouse hepatitis virus
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Peng, Hui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Zhao-Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Gang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Zi-Tong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Zhi-Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koup, Richard A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bailer, Robert T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Chang-You
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 120(2006), 2 vom: 15. Aug., Seite 171-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:120
|g year:2006
|g number:2
|g day:15
|g month:08
|g pages:171-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 120
|j 2006
|e 2
|b 15
|c 08
|h 171-8
|